{"id":56024,"date":"2015-10-27T10:29:20","date_gmt":"2015-10-27T09:29:20","guid":{"rendered":"http:\/\/www.r-biopharm.com\/?p=56024"},"modified":"2019-05-09T09:24:20","modified_gmt":"2019-05-09T07:24:20","slug":"ced-erkrankungen-tnf-blocker-calprotectin","status":"publish","type":"post","link":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/","title":{"rendered":"CED-Erkrankungen \u2013 TNF\u03b1-Blocker &#038; Calprotectin"},"content":{"rendered":"<div class=\"wpb-content-wrapper\">[vc_row][vc_column][vc_column_text css=&#8220;.vc_custom_1557386657207{margin-bottom: 0px !important;}&#8220;]<strong>Chronisch entz\u00fcndliche Darmerkrankungen (CED) sind gekennzeichnet durch wiederkehrende und teils anhaltende Krankheitssch\u00fcbe. Die beiden h\u00e4ufigsten Formen der CED sind Morbus Crohn und Colitis ulcerosa.<\/strong><!--more--><\/p>\n<h3>Den Entz\u00fcndungskreislauf stoppen mit TNF\u03b1-Blockern<\/h3>\n<p>Die chronische Entz\u00fcndung basiert auf einer aus der Balance geratenen Immunantwort, die durch Aussch\u00fcttung von TNF\u03b1 (Tumornekrosefaktor alpha) kontinuierlich das Signal zur Entz\u00fcndungsverst\u00e4rkung sendet. Diese Signalkaskade kann durch bestimmte Medikamente wie die TNF\u03b1-Blocker unterbrochen werden, um auf diese Weise die Entz\u00fcndung zu vermindern oder zu stoppen. <strong>Infliximab<\/strong> sowie <strong>Adalimumab<\/strong> sind solche Medikamente und werden h\u00e4ufig bei CED-Erkrankungen eingesetzt.<\/p>\n<h3>Medikamenten-Monitoring von TNF\u03b1-Blockern<\/h3>\n<p>Wesentlich f\u00fcr die erfolgreiche Behandlung mit TNF\u03b1-Blockern ist das Medikamenten-Monitoring. Durch regelm\u00e4\u00dfige \u00dcberpr\u00fcfung der Wirkstoffkonzentration im Blut kann die optimale Dosierung individuell f\u00fcr jeden Patienten ermittelt werden. Diese unterscheidet sich aufgrund von Unterschieden im Stoffwechsel von Mensch zu Mensch.<\/p>\n<p>Medikamenten-Monitoring von Infliximab kann z. B. mit RIDASCREEN\u00ae IFX Monitoring durchgef\u00fchrt werden. Der Assay basiert auf dem home-brew Test der KU Leuven und wurde in klinischen Studien validiert.<\/p>\n<p>Erfahren Sie mehr \u00fcber den Assay auf der <a href=\"http:\/\/www.r-biopharm.com\/de\/produkte\/klinische-diagnostik\/gastroenterologie\/entzuendliche-darmerkrankungen\/item\/ridascreen-ifx-monitoring\">Produktseite<\/a>.<\/p>\n<h3>Monitoring der Entz\u00fcndungsst\u00e4rke<\/h3>\n<p>Parallel zum Medikamenten-Monitoring kann der Erfolg der Behandlung, also der R\u00fcckgang der Entz\u00fcndungsst\u00e4rke, durch die regelm\u00e4\u00dfige Analyse von Calprotectin im Stuhl \u00fcberpr\u00fcft werden. Calprotectin ist ein Protein, das in Zellen des Immunsystems vorkommt und bei Entz\u00fcndungen freigesetzt wird. Die Calprotectin-Konzentration im Stuhl korreliert mit der Entz\u00fcndungsst\u00e4rke im Darm.<\/p>\n<p>Die Calprotectin-Konzentration kann z. B. mit RIDASCREEN\u00ae Calprotectin nachgewiesen werden. <a href=\"http:\/\/www.r-biopharm.com\/de\/produkte\/klinische-diagnostik\/gastroenterologie\/entzuendliche-darmerkrankungen\/item\/ridascreen-calprotectin-neue-version\">Hier erfahren Sie mehr \u00fcber den Assay.<\/a>[\/vc_column_text][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text css=&#8220;.vc_custom_1557386657207{margin-bottom: 0px !important;}&#8220;]Chronisch entz\u00fcndliche Darmerkrankungen (CED) sind gekennzeichnet durch wiederkehrende und teils anhaltende Krankheitssch\u00fcbe. Die beiden h\u00e4ufigsten Formen der CED sind Morbus Crohn und Colitis ulcerosa.<\/p>\n","protected":false},"author":324,"featured_media":86961,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[239,252],"tags":[],"class_list":["post-56024","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gastroenterologie","category-therapeutisches-drug-monitoring"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CED-Erkrankungen \u2013 TNF\u03b1-Blocker &amp; Calprotectin (de) - Clinical Diagnostics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CED-Erkrankungen \u2013 TNF\u03b1-Blocker &amp; Calprotectin (de) - Clinical Diagnostics\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_column_text css=&#8220;.vc_custom_1557386657207{margin-bottom: 0px !important;}&#8220;]Chronisch entz\u00fcndliche Darmerkrankungen (CED) sind gekennzeichnet durch wiederkehrende und teils anhaltende Krankheitssch\u00fcbe. Die beiden h\u00e4ufigsten Formen der CED sind Morbus Crohn und Colitis ulcerosa.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Diagnostics\" \/>\n<meta property=\"article:published_time\" content=\"2015-10-27T09:29:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-05-09T07:24:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/10\/TNFalpha-blocker-Calprotectin-IBD1-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"690\" \/>\n\t<meta property=\"og:image:height\" content=\"252\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"aschlereth\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"aschlereth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/\"},\"author\":{\"name\":\"aschlereth\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed\"},\"headline\":\"CED-Erkrankungen \u2013 TNF\u03b1-Blocker &#038; Calprotectin\",\"datePublished\":\"2015-10-27T09:29:20+00:00\",\"dateModified\":\"2019-05-09T07:24:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/\"},\"wordCount\":288,\"image\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/10\/TNFalpha-blocker-Calprotectin-IBD1-1.jpg\",\"articleSection\":[\"Gastroenterologie\",\"Therapeutisches Drug Monitoring\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/\",\"url\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/\",\"name\":\"CED-Erkrankungen \u2013 TNF\u03b1-Blocker & Calprotectin (de) - Clinical Diagnostics\",\"isPartOf\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/10\/TNFalpha-blocker-Calprotectin-IBD1-1.jpg\",\"datePublished\":\"2015-10-27T09:29:20+00:00\",\"dateModified\":\"2019-05-09T07:24:20+00:00\",\"author\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed\"},\"breadcrumb\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#primaryimage\",\"url\":\"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/10\/TNFalpha-blocker-Calprotectin-IBD1-1.jpg\",\"contentUrl\":\"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/10\/TNFalpha-blocker-Calprotectin-IBD1-1.jpg\",\"width\":690,\"height\":252},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/clinical.r-biopharm.com\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CED-Erkrankungen \u2013 TNF\u03b1-Blocker &#038; Calprotectin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#website\",\"url\":\"https:\/\/clinical.r-biopharm.com\/fr\/\",\"name\":\"Clinical Diagnostics\",\"description\":\"A Division of the R-Biopharm Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/clinical.r-biopharm.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed\",\"name\":\"aschlereth\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2a8584ee89568ed5fc12875426a8801f1d5be5cef5a0cb5f54f1a866a4d2fb57?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2a8584ee89568ed5fc12875426a8801f1d5be5cef5a0cb5f54f1a866a4d2fb57?s=96&d=mm&r=g\",\"caption\":\"aschlereth\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CED-Erkrankungen \u2013 TNF\u03b1-Blocker & Calprotectin (de) - Clinical Diagnostics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/","og_locale":"de_DE","og_type":"article","og_title":"CED-Erkrankungen \u2013 TNF\u03b1-Blocker & Calprotectin (de) - Clinical Diagnostics","og_description":"[vc_row][vc_column][vc_column_text css=&#8220;.vc_custom_1557386657207{margin-bottom: 0px !important;}&#8220;]Chronisch entz\u00fcndliche Darmerkrankungen (CED) sind gekennzeichnet durch wiederkehrende und teils anhaltende Krankheitssch\u00fcbe. Die beiden h\u00e4ufigsten Formen der CED sind Morbus Crohn und Colitis ulcerosa.","og_url":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/","og_site_name":"Clinical Diagnostics","article_published_time":"2015-10-27T09:29:20+00:00","article_modified_time":"2019-05-09T07:24:20+00:00","og_image":[{"width":690,"height":252,"url":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/10\/TNFalpha-blocker-Calprotectin-IBD1-1.jpg","type":"image\/jpeg"}],"author":"aschlereth","twitter_misc":{"Verfasst von":"aschlereth","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#article","isPartOf":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/"},"author":{"name":"aschlereth","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed"},"headline":"CED-Erkrankungen \u2013 TNF\u03b1-Blocker &#038; Calprotectin","datePublished":"2015-10-27T09:29:20+00:00","dateModified":"2019-05-09T07:24:20+00:00","mainEntityOfPage":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/"},"wordCount":288,"image":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#primaryimage"},"thumbnailUrl":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/10\/TNFalpha-blocker-Calprotectin-IBD1-1.jpg","articleSection":["Gastroenterologie","Therapeutisches Drug Monitoring"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/","url":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/","name":"CED-Erkrankungen \u2013 TNF\u03b1-Blocker & Calprotectin (de) - Clinical Diagnostics","isPartOf":{"@id":"https:\/\/clinical.r-biopharm.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#primaryimage"},"image":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#primaryimage"},"thumbnailUrl":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/10\/TNFalpha-blocker-Calprotectin-IBD1-1.jpg","datePublished":"2015-10-27T09:29:20+00:00","dateModified":"2019-05-09T07:24:20+00:00","author":{"@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed"},"breadcrumb":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#primaryimage","url":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/10\/TNFalpha-blocker-Calprotectin-IBD1-1.jpg","contentUrl":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2015\/10\/TNFalpha-blocker-Calprotectin-IBD1-1.jpg","width":690,"height":252},{"@type":"BreadcrumbList","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/ced-erkrankungen-tnf-blocker-calprotectin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clinical.r-biopharm.com\/de\/"},{"@type":"ListItem","position":2,"name":"CED-Erkrankungen \u2013 TNF\u03b1-Blocker &#038; Calprotectin"}]},{"@type":"WebSite","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#website","url":"https:\/\/clinical.r-biopharm.com\/fr\/","name":"Clinical Diagnostics","description":"A Division of the R-Biopharm Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clinical.r-biopharm.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed","name":"aschlereth","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2a8584ee89568ed5fc12875426a8801f1d5be5cef5a0cb5f54f1a866a4d2fb57?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2a8584ee89568ed5fc12875426a8801f1d5be5cef5a0cb5f54f1a866a4d2fb57?s=96&d=mm&r=g","caption":"aschlereth"}}]}},"_links":{"self":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/56024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/users\/324"}],"replies":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/comments?post=56024"}],"version-history":[{"count":1,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/56024\/revisions"}],"predecessor-version":[{"id":97040,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/56024\/revisions\/97040"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media\/86961"}],"wp:attachment":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media?parent=56024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/categories?post=56024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/tags?post=56024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}